Literature DB >> 17303592

Atypical parkinsonism in Guadeloupe: a common risk factor for two closely related phenotypes?

Annie Lannuzel1, G U Höglinger, S Verhaeghe, L Gire, S Belson, M Escobar-Khondiker, P Poullain, W H Oertel, E C Hirsch, B Dubois, M Ruberg.   

Abstract

In Guadeloupe, there is an abnormally high frequency of atypical parkinsonism. Only one-third of the patients that develop parkinsonian symptoms were reported to present the classical features of idiopathic Parkinson disease and one-third a syndrome resembling progressive supranuclear palsy (PSP). The others were unclassifiable, according to established criteria. We carried out a cross-sectional study of 160 parkinsonian patients to: (i) define more precisely the clinical phenotypes of the PSP-like syndrome and the parkinsonism that was considered unclassifiable in comparison with previously known disorders; (ii) define the neuropsychological and brain imaging features of these patients; (iii) evaluate to what extent a candidate aetiological factor, the mitochondrial complex I inhibitor annonacin contained in the fruit and leaves of the tropical plant Annona muricata (soursop) plays a role in the neurological syndrome. Neuropsychological tests and MRI were used to classify the patients into those with Parkinson's disease (31%), Guadeloupean PSP-like syndrome (32%), Guadeloupean parkinsonism-dementia complex (PDC, 31%) and other parkinsonism-related disorders (6%). Patients with a PSP-like syndrome developed levodopa-resistant parkinsonism, associated with early postural instability and supranuclear oculomotor dysfunction. They differed, however, from classical PSP patients by the frequency of tremor (>50%), dysautonomia (50%) and the occurrence of hallucinations (59%). PDC patients had levodopa-resistant parkinsonism associated with frontosubcortical dementia, 52% of these patients had hallucinations, but, importantly, none had oculomotor dysfunction. The pattern of neuropsychological deficits was similar in both subgroups. Cerebral atrophy was seen in the majority of the PSP-like and PDC patients, with enlargement of the third ventricle and marked T2-hypointensity in the basal ganglia, particularly the substantia nigra. Consumption of soursop was significantly greater in both PSP-like and PDC patients than in controls and Parkinson's disease patients. In conclusion, atypical Guadeloupean parkinsonism comprises two forms of parkinsonism and dementia that differ clinically by the presence of oculomotor signs, but have similar cognitive profiles and neuroimaging features, suggesting that they may constitute a single disease entity, and both were similarly exposed to annonaceous neurotoxins, notably annonacin.

Entities:  

Mesh:

Year:  2007        PMID: 17303592     DOI: 10.1093/brain/awl347

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  23 in total

1.  Environmental neurotoxin-induced progressive model of parkinsonism in rats.

Authors:  Wei-Bin Shen; Kimberly A McDowell; Aubrey A Siebert; Sarah M Clark; Natalie V Dugger; Kimberly M Valentino; H A Jinnah; Carole Sztalryd; Paul S Fishman; Christopher A Shaw; M Samir Jafri; Paul J Yarowsky
Journal:  Ann Neurol       Date:  2010-07       Impact factor: 10.422

2.  POLG and PEO1 (Twinkle) mutations are infrequent in PSP-like atypical parkinsonism: a preliminary screening study.

Authors:  Matthis Synofzik; Julia Schicks; Karin Srulijes; Claudia Schulte; Franziska Schiele; Daniela Berg; Ludger Schöls
Journal:  J Neurol       Date:  2012-05-12       Impact factor: 4.849

3.  Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study.

Authors:  Lisa F Potts; Alex C Cambon; Owen A Ross; Rosa Rademakers; Dennis W Dickson; Ryan J Uitti; Zbigniew K Wszolek; Shesh N Rai; Matthew J Farrer; David W Hein; Irene Litvan
Journal:  BMC Med Genet       Date:  2012-03-17       Impact factor: 2.103

4.  Tauopathy-associated PERK alleles are functional hypomorphs that increase neuronal vulnerability to ER stress.

Authors:  Shauna H Yuan; Nobuhiko Hiramatsu; Qing Liu; Xuehan Victoria Sun; David Lenh; Priscilla Chan; Karen Chiang; Edward H Koo; Aimee W Kao; Irene Litvan; Jonathan H Lin
Journal:  Hum Mol Genet       Date:  2018-11-15       Impact factor: 6.150

Review 5.  Clinical effects of chemical exposures on mitochondrial function.

Authors:  Zarazuela Zolkipli-Cunningham; Marni J Falk
Journal:  Toxicology       Date:  2017-07-27       Impact factor: 4.221

6.  Progressive supranuclear palsy and pawpaw.

Authors:  Bonnie Kaas; Argye E Hillis; Alexander Pantelyat
Journal:  Neurol Clin Pract       Date:  2020-04

Review 7.  Clinical trials in REM sleep behavioural disorder: challenges and opportunities.

Authors:  Aleksandar Videnovic; Yo-El S Ju; Isabelle Arnulf; Valérie Cochen-De Cock; Birgit Högl; Dieter Kunz; Federica Provini; Pietro-Luca Ratti; Mya C Schiess; Carlos H Schenck; Claudia Trenkwalder
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-05-13       Impact factor: 10.154

Review 8.  Mitochondrial dysfunction as a therapeutic target in progressive supranuclear palsy.

Authors:  Vincent Ries; Wolfgang H Oertel; Günter U Höglinger
Journal:  J Mol Neurosci       Date:  2011-07-27       Impact factor: 3.444

Review 9.  Neurodegenerative diseases: neurotoxins as sufficient etiologic agents?

Authors:  Christopher A Shaw; Günter U Höglinger
Journal:  Neuromolecular Med       Date:  2007-11-06       Impact factor: 3.843

10.  REM sleep behavior disorder in patients with guadeloupean parkinsonism, a tauopathy.

Authors:  Valérie Cochen De Cock; Annie Lannuzel; Stéphane Verhaeghe; Emmanuel Roze; Merle Ruberg; Jean Philippe Derenne; Jean Claude Willer; Marie Vidailhet; Isabelle Arnulf
Journal:  Sleep       Date:  2007-08       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.